WA
BIIB icon

Waddell & Associates’s Biogen BIIB Stock Holding History

Waddell & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$641K Buy
2,967
+703
+31% +$134K 0.03% 211
2026
Q1 		$415K Buy
2,264
+522
+30% +$96.2K 0.02% 275
2025
Q4 		$307K Buy
1,742
+23
+1% +$3.76K 0.02% 273
2025
Q3 		$241K Buy
+1,719
New +$232K 0.02% 267
2024
Q1 		– Sell
-838
Closed -$217K – 144
2023
Q4 		$217K Sell
838
-49
-6% -$12K 0.03% 142
2023
Q3 		$228K Hold
887
– – 0.03% 156
2023
Q2 		$253K Hold
887
– – 0.04% 148
2023
Q1 		$247K Sell
887
-6
-0.7% -$1.66K 0.04% 134
2022
Q4 		$247K Buy
893
+6
+0.7% +$1.7K 0.04% 128
2022
Q3 		$237K Buy
+887
New +$188K 0.05% 115
2022
Q1 		– Sell
-887
Closed -$213K – 131
2021
Q4 		$213K Hold
887
– – 0.03% 117
2021
Q3 		$251K Hold
887
– – 0.04% 91
2021
Q2 		$307 Buy
+887
New +$269K 0.05% 96

Other funds holding BIIB

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Waddell & Associates's BIIB Position: Q2 2026 in Review

Waddell & Associates increased its Biogen (BIIB) stake by 31% in Q2 2026, buying an estimated $134K and bringing the position to 2,967 shares worth $641K. The position accounts for 0.03% of the portfolio, ranked #211.

Waddell & Associates first reported a position in BIIB in Q2 2021 and has held it in 13 quarters since. 162 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Waddell & Associates held 2,967 shares of Biogen worth $641K as of Q2 2026.
  • Waddell & Associates bought 703 Biogen shares in Q2 2026, an estimated $134K.
  • Biogen made up 0.03% of Waddell & Associates's portfolio in Q2 2026, its #211 holding.
  • Waddell & Associates first reported a position in Biogen in Q2 2021 and has held it in 13 quarters since.
  • 162 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.